Halozyme Therapeutics (HALO) reported $290.08 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 34.3%. EPS of $1.27 for the same period compares to $0.75 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $248.01 million, representing a surprise of +16.97%. The company delivered an EPS surprise of +28.28%, with the consensus EPS estimate being $0.99.While investors closely watch year-over-year changes in headline numbers -- revenue an ...